Interaksi Estazolam dan Suvoreksant

Estazolam dan Suvoreksant: kedua label peresepan menandai kombinasi ini dengan bahasa yang paling tegas, seperti kontraindikasi, peringatan kotak hitam, atau instruksi untuk menghindarinya.

Mayor

Jangan dikombinasikan tanpa arahan dokter yang meresepkan. Bahasa label di bawah ini adalah yang paling tegas yang digunakan FDA.

Apa kata label FDA

Dari label Estazolam · berlaku sejak 2024-02-05

Mayor

Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A (see CONTRAINDICATIONS ).

Peringatanberdasarkan golongan obatLihat label di DailyMed
Moderat

Although behaviors such as sleep-driving may occur with sedative-hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with sedative-hypnotics appears to increase the risk of such behaviors, as does the use of sedative-hypnotics at doses exceeding the maximum recommended dose.

Peringatanberdasarkan golongan obatLihat label di DailyMed
Moderat

Patients should also be cautioned about possible combined effects with alcohol and other CNS depressant drugs.

Peringatanberdasarkan golongan obatLihat label di DailyMed
Moderat

The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Minor

Estazolam, like other benzodiazepines, has CNS depressant effects.

Peringatanberdasarkan golongan obatLihat label di DailyMed

Dari label Suvoreksant (BELSOMRA) · berlaku sejak 2025-03-10

Moderat

CNS Depressant Effects and Daytime Impairment: Risk of impaired alertness and motor coordination, including impaired driving; risk increases with dose; caution patients taking 20 mg against next-day driving and other activities requiring complete mental alertness ( 5.1 ).

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

Prescribers should monitor for somnolence and CNS depressant effects, but impairment can occur in the absence of symptoms, and may not be reliably detected by ordinary clinical exam (i.e., less than formal testing of daytime wakefulness and/or psychomotor performance).

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression.

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

Dosage adjustments of BELSOMRA and of concomitant CNS depressants may be necessary when administered together because of potentially additive effects.

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

The risk of next-day impairment, including impaired driving, is increased if BELSOMRA is taken with less than a full night of sleep remaining, if a higher than the recommended dose is taken, if co-administered with other CNS depressants, or if co-administered with other drugs that increase blood levels of BELSOMRA.

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed

Menggunakan lebih dari dua obat ini? Interaksi saling bertumpuk. Periksa seluruh daftar Anda sekaligus; daftar itu tetap berada di peramban Anda.

Buka di pemeriksa

Bukan nasihat medis. Interaction Checker mengutip teks label FDA dan lembar fakta NIH. Penting atau tidaknya suatu interaksi bagi Anda bergantung pada dosis, waktu penggunaan, fungsi ginjal dan hati, serta kondisi lain. Pastikan dengan apoteker atau dokter yang meresepkan.